RNA-Seq analysis of kidney transcriptome profiles in young spontaneously hypertensive rats and revealing the protective effects and potential therapeutic targets of SGLT2 inhibitors in early hypertensive nephropathy

Hypertensive nephropathy is a common complication of hypertension that places a heavy burden on society. SGLT2 inhibitors are a new class of hypoglycemic agents that have been shown to have specific protective effects on the kidneys. This study aimed to investigate the early changes in renal transcription spectrum in spontaneously hypertensive rats and the effects of DAPA, a sodium-glucose cotransporter 2 inhibitor, on the remission of hypertensive nephropathy and its underlying molecular mechanisms. We furthermore show thatSGLT2 inhibitors may reduce inflammation and improve energy metabolism by regulating the expression of SLC9a3, Zbtb20, Trim50 and Ccnl2.高血压肾病（Hypertensive nephropathy）是高血压的常见并发症，给社会造成沉重负担。钠-葡萄糖协同转运蛋白2抑制剂（SGLT2 inhibitors）是一类新型降糖药物，现已被证实对肾脏具有特异性保护作用。本研究旨在探究自发性高血压大鼠肾脏转录谱的早期变化，以及DAPA（一种钠-葡萄糖协同转运蛋白2抑制剂）对高血压肾病缓解的作用及其潜在分子机制。本研究进一步证实，钠-葡萄糖协同转运蛋白2抑制剂可通过调控SLC9a3、Zbtb20、Trim50及Ccnl2的表达，减轻炎症反应并改善能量代谢。